BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 37151176)

  • 21. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
    Han Y; Xie W; Song DG; Powell DJ
    J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cells engineered with full-length NKG2D linked to signaling domains of 4-1BB and CD3ζ show enhanced antitumor activity.
    Teng X; Rong Z; Li S; Yang W; Lu Z
    Immunol Cell Biol; 2023 May; 101(5):458-464. PubMed ID: 36811384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
    Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Annihilation of Non-small Cell Lung Cancer by NKG2D CAR-T Cells Produced from T Cells from Peripheral Blood of Healthy Donors.
    Jiang J; Liu Y; Zeng Y; Fang B; Chen Y
    J Interferon Cytokine Res; 2023 Oct; 43(10):445-454. PubMed ID: 37819621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
    Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
    Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia
    Ibáñez-Navarro M; Fernández A; Escudero A; Esteso G; Campos-Silva C; Navarro-Aguadero MÁ; Leivas A; Caracuel BR; Rodríguez-Antolín C; Ortiz A; Navarro-Zapata A; Mestre-Durán C; Izquierdo M; Balaguer-Pérez M; Ferreras C; Martínez-López J; Valés-Gómez M; Pérez-Martínez A; Fernández L
    Front Immunol; 2023; 14():1187665. PubMed ID: 37928520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
    Baumeister SH; Murad J; Werner L; Daley H; Trebeden-Negre H; Gicobi JK; Schmucker A; Reder J; Sentman CL; Gilham DE; Lehmann FF; Galinsky I; DiPietro H; Cummings K; Munshi NC; Stone RM; Neuberg DS; Soiffer R; Dranoff G; Ritz J; Nikiforow S
    Cancer Immunol Res; 2019 Jan; 7(1):100-112. PubMed ID: 30396908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer.
    Zhang Y; Zhang C; He M; Xing W; Hou R; Zhang H
    BMC Cancer; 2024 Jan; 24(1):119. PubMed ID: 38263004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer.
    Zhou Z; Li J; Hong J; Chen S; Chen M; Wang L; Lin W; Ye Y
    Front Immunol; 2022; 13():1002361. PubMed ID: 36618357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
    Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
    Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
    [No Abstract]   [Full Text] [Related]  

  • 32. Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis.
    Jiang G; Ng YY; Tay JCK; Du Z; Xiao L; Wang S; Zhu J
    Cancer Immunol Immunother; 2023 Jan; 72(1):223-234. PubMed ID: 35809118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming Target Driven Fratricide for T Cell Therapy.
    Breman E; Demoulin B; Agaugué S; Mauën S; Michaux A; Springuel L; Houssa J; Huberty F; Jacques-Hespel C; Marchand C; Marijsse J; Nguyen T; Ramelot N; Violle B; Daro D; De Waele P; Gilham DE; Steenwinckel V
    Front Immunol; 2018; 9():2940. PubMed ID: 30619300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
    Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
    Front Immunol; 2019; 10():2361. PubMed ID: 31649672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer.
    Ye J; Liu Q; He Y; Song Z; Lin B; Hu Z; Hu J; Ning Y; Cai C; Li Y
    J Transl Med; 2024 Feb; 22(1):171. PubMed ID: 38368374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NKG2D CARs as cell therapy for cancer.
    Sentman CL; Meehan KR
    Cancer J; 2014; 20(2):156-9. PubMed ID: 24667963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR.
    Li Z; Chi Z; Ang WX; Chen C; Tay JC; Ng YY; Xu X; Wang J; Zhu J; Wang S
    Immunotherapy; 2020 Jul; 12(10):733-748. PubMed ID: 32571133
    [No Abstract]   [Full Text] [Related]  

  • 38. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma.
    Meister H; Look T; Roth P; Pascolo S; Sahin U; Lee S; Hale BD; Snijder B; Regli L; Ravi VM; Heiland DH; Sentman CL; Weller M; Weiss T
    Clin Cancer Res; 2022 Nov; 28(21):4747-4756. PubMed ID: 36037304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
    Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.